中國農產品交易(00149.HK)中期盈轉虧至2256.7萬港元
格隆匯 11 月 24日丨中國農產品交易(00149.HK)公佈,截至2020年6月30日止中期,公司實現營業額2.92億港元,同比減少36.77%;公司擁有人淨虧2256.7萬港元,去年同期則錄得純利819.4萬港元,盈轉虧;基本每股淨虧0.23港仙。無派息。
於爆發新冠肺炎疫情期間,中國政府已採取各種措施以控制新冠肺炎疫情迅速傳播,包括限制人員及車輛活動,以及加強公共市場衞生管制。該等措施令市場交易活動放緩,導致相關佣金收入減少。
然而,由於業務性質及中國新冠肺炎疫情得以迅速受控,對市場影響屬暫時性,市場交易量及收入已恢復正常水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.